

ANTIGENICS INC /DE/
Form 3
July 24, 2006

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Wentworth Kerry
(Last) (First) (Middle)

C/O ANTIGENICS INC., 630
FIFTH AVENUE, SUITE 2100

(Street)

NEW YORK, NY 10111

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)
07/20/2006

3. Issuer Name and Ticker or Trading Symbol
ANTIGENICS INC /DE/ [AGEN]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director ____ 10% Owner
X Officer ____ Other
(give title below) (specify below)
VP, Reg Affairs & Clinical Ops

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Common Stock ⁽⁴⁾

2,500 ⁽⁴⁾

D A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

Date Exercisable

3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)

Title

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security:
Direct (D)

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Edgar Filing: ANTIGENICS INC /DE/ - Form 3

	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Stock Option, right to buy	11/01/2005 ⁽¹⁾	11/01/2014	Common Stock	40,000	\$ 6.77	D Â
Stock Option, right to buy	03/22/2007 ⁽²⁾	03/22/2016	Common Stock	20,000	\$ 5.13	D Â
Stock Option, right to buy	06/14/2007 ⁽³⁾	06/14/2016	Common Stock	60,000	\$ 2.03	D Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wentworth Kerry C/O ANTIGENICS INC. 630 FIFTH AVENUE, SUITE 2100 NEW YORK, NY 10111	Â	Â	Â VP, Reg Affairs & Clinical Ops	Â

Signatures

Christine M. Klaskin, by Power of
Attorney

07/24/2006

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Options vest in four equal annual installments beginning 11/1/2005.

(2) Options vest in three equal annual installments beginning 3/22/07.

(3) Options vest in four equal annual installments beginning 6/14/2007.

(4) These shares will vest in 2 installments, one-third on 3/22/2007 and two-thirds on 3/22/2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.